Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Interleukin-12 receptor subunit beta-1/Interleukin-12 receptor subunit beta-2 (IL12RB1/IL12RB2) receptor complex is a heterodimeric type I cytokine receptor that serves as the functional receptor for interleukin-12 (IL-12). It is primarily expressed on activated T cells, natural killer (NK) cells, and dendritic cells. The IL12RB1 subunit binds to the p40 subunit of IL-12 with low affinity, while the IL12RB2 subunit acts as the signal-transducing component. Upon IL-12 binding, the subunits heterodimerize to form a high-affinity complex, initiating intracellular signaling through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, specifically activating JAK2, TYK2, and STAT4. This signaling cascade is crucial for driving the differentiation of naive CD4+ T cells into T helper 1 (Th1) cells and stimulating the production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha).\n\nDysregulation of the IL-12/IL-12R pathway is implicated in various autoimmune and inflammatory diseases, such as psoriasis, Crohn's disease, and ulcerative colitis, where overactivation leads to chronic inflammation. Conversely, loss-of-function mutations in the receptor subunits, particularly IL12RB1, lead to Mendelian susceptibility to mycobacterial diseases (MSMD), characterized by severe infections with weakly virulent mycobacteria and Salmonella. In oncology, the receptor complex is a target for pro-inflammatory cancer immunotherapies, as IL-12 signaling can enhance anti-tumor immune responses by activating cytotoxic T lymphocytes and NK cells. Therapeutic agents targeting this pathway include monoclonal antibodies like ustekinumab and briakinumab, which block the interaction of IL-12 with the receptor complex to treat autoimmune disorders, and recombinant IL-12 formulations (such as edodekin alfa) that act as agonists to stimulate anti-tumor immunity, though systemic toxicity remains a major challenge for the latter.
Antagonists (such as ustekinumab and briakinumab) bind to the shared p40 subunit of IL-12 and IL-23, preventing their interaction with the IL-12Rbeta1 subunit of the receptor complex and thereby blocking downstream JAK-STAT signaling. Agonists (such as edodekin alfa) bind directly to the IL-12Rbeta1/IL-12Rbeta2 complex, activating JAK2/TYK2 and STAT4 to promote Th1 differentiation and interferon-gamma production.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-12 receptor complex (IL-12R).